Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
about
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCThe mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsRole of HER2 in NSCLCA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureProfile of neratinib and its potential in the treatment of breast cancerReview of the current targeted therapies for non-small-cell lung cancerPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsHER2 activating mutations are targets for colorectal cancer treatmentRecent developments and translational aspects in targeted therapy for metastatic breast cancerTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsImplementation of adaptive methods in early-phase clinical trials.Identifying a maximum tolerated contour in two-dimensional dose finding.Practical designs for Phase I combination studies in oncologyA comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.How may targeted proteomics complement genomic data in breast cancer?ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Molecular pathways and therapeutic targets in lung cancerBosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Targeted therapy in NSCLC driven by HER2 insertionsPyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid TumorsHighly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR methodHER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Institutional implementation of clinical tumor profiling on an unselected cancer population.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.Adaptive Randomization of Neratinib in Early Breast Cancer.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.The role of neratinib in HER2-driven breast cancer.Neratinib for the treatment of HER2-positive early stage breast cancer.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.Combine and conquer: challenges for targeted therapy combinations in early phase trials.
P2860
Q26747276-5AE764A0-8F25-45E9-84CC-3511EBBBA484Q26751155-1FEAD84B-D333-40CF-83AB-89A77D352A47Q26781683-799550E4-9A99-4D50-8106-3FD9993A5BA0Q26797297-49F8D709-F8B6-4645-9CC3-25D92F160B63Q26996348-B5A68CD7-44F9-40D3-8492-4F8F3C8C55FCQ27012540-20D91BCF-31A7-4B80-8BA8-DC4E44D1BE90Q27015079-FAE51172-8DED-42BC-840A-D8BB42B8C477Q27025970-292F6A26-BF8B-46F5-98D0-788AF61D58E1Q27853154-C9D3FFCC-81F9-491E-BEFF-079B518BB129Q27853193-CE4E3539-552A-465B-8EDF-C3ED16D38437Q28072755-88C02832-9671-451B-A7E2-976D022B4FFCQ28083446-B0C218BF-7238-4E25-9A22-3DB11FC0AF00Q28086768-3F01C5E4-F47F-4A1C-8F83-6FF36BDEAF7AQ30277243-EE688CD2-A426-46CD-AECF-EFBF26A93F7DQ30277277-C6EE7B93-7C24-49A7-8B7E-B0932095A577Q30278669-8EA8DEBD-A6C1-4D06-A483-ECBD7255DB87Q30299951-ACC2142A-C8E6-4002-A19D-ED885DFD0963Q30857631-32B09134-57EC-4942-A8D0-05F881BA3452Q31140924-BBF2309C-20F5-4836-B0F2-C2D5ED8BF3E1Q33601653-C595C065-2868-46B4-A5C4-6FD52002CEB9Q33688872-AF689DA3-D444-4E61-A8F2-94DFEC78575BQ34658293-CA0E6CEF-24AD-423D-9FEE-F7E304980E4AQ35136424-5F62BDB3-5797-4DB1-84C5-2333AC6A514EQ35200528-132C0B84-52FB-47E5-9681-252079896A4CQ36088709-BD134F34-0E08-4DF7-B924-695A1706FC8EQ36147793-46AA9002-53BA-4757-B1DC-098263E2C6D2Q36267612-D5900403-6B21-41E2-B3D4-EC3CD5332995Q36430534-A7D71748-D271-42AB-A296-74DACA2C5867Q37353957-A9A2FEB9-37AB-4601-A59B-5480CA83D460Q37417570-80D95B93-DA92-4E4D-A7F5-4FC16BA697F8Q37455251-967C9B59-B45A-45B3-A790-E07C6BE2AFDBQ37601709-45849FFE-7C60-4789-8DE9-DE68157C59CEQ37743107-F358A1DB-B738-4D59-B90A-622436150202Q38192017-08CF4DD2-A3D5-415B-BA90-0AABE4BBACB1Q38242086-43F42ADB-850E-4AA4-A20F-9447D2E9C559Q38661973-2AED52F6-721B-40B8-A722-0F833A727EF7Q38664492-5C721C83-0471-4B41-9BD2-EB4647060D19Q38666768-ACF2A71C-5F64-4F1E-B105-A06DC63B16CAQ38728508-BA469041-4AC0-4D35-B67B-4511F13B3D47Q38734451-136E52F1-2320-4765-A637-240125E77CBE
P2860
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase I study of neratinib in ...... endent and other solid tumors.
@en
Phase I study of neratinib in ...... endent and other solid tumors.
@nl
type
label
Phase I study of neratinib in ...... endent and other solid tumors.
@en
Phase I study of neratinib in ...... endent and other solid tumors.
@nl
prefLabel
Phase I study of neratinib in ...... endent and other solid tumors.
@en
Phase I study of neratinib in ...... endent and other solid tumors.
@nl
P2093
P356
P1476
Phase I study of neratinib in ...... endent and other solid tumors.
@en
P2093
Anna Berkenblit
Antoine Hollebecque
Eunice L Kwak
Geoffrey I Shapiro
James M Cleary
Kathleen W Turnbull
Mizue Krygowski
Rastislav Bahleda
Revathi Ananthakrishnan
Richat Abbas
P356
10.1200/JCO.2012.47.2787
P407
P577
2013-12-09T00:00:00Z